-Advertisement-
-Advertisement-
Hematology
Long-term follow-up shows ravulizumab effective in paroxysmal nocturnal hemoglobinuria
In this study, 441 patients from 2 pivotal phase 3 studies comparing ravulizumab to eculizumab in complement inhibitor-naïve (n = 301) and complement inhibitor-experienced (n = 302) patients with paroxysmal nocturnal hemoglobinuria after 26 weeks of treatment, continued treatment with ravulizumab throughout the extension period. During the extension period, improvements...
Read More By rd360stg
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
By rd360stg
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
info@ihmholdings.com
QUICK LINKS
© 2022 IHM. RD 360 is a trademark of International Healthcare Media, LLC. All rights Reserved